San Diego-based mostly Viking Therapeutics marked itself as a significant competitor from the weight loss drug market in February immediately after revealing promising facts from the mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when supplied as being a weekly injection As well as